Located in Provincial Chemical Industry Park, Jiande Railway New District, Zhejiang province, Allsino Pharmaceutical Co., LTD. (stock code 688076) was established in May 2004 covering an area of 97,350 m2. We specializes in the research, development, production of RSMs, GMP intermediates and APIs. Products are mainly exported to the United States, Europe, Japan and other developed countries and regions.

We have 650+ employees, including 350+ with college degrees or higher (40+ master's/Ph.D., 180+ bachelor's). Through independent R&D and international technical cooperation, Allsino has developed over 400 projects relating to the therapeutic areas of anti-cancer, antiviral, antidepressant, anti-hepatitis, and metabolic system medications. Some of these projects have already entered commercial production.

Allsino operates a provincial-level biopharmaceutical research institute, a postdoctoral workstation, and an expert workstation. With a strong focus on R&D, Allsino has built leading expertise in small-molecule organic synthesis, chiral synthesis, and peptide synthesis (solid/liquid-phase).

It holds 21 patents and 7 utility model patents and maintains long-term technical partnerships with global pharmaceutical leaders, including Fortune 500 companies Eli Lilly and Merck & Co., Inc.

Allsino is ISO 9001, ISO 14001, and ISO 45001 certified and has passed NMPA GMP audits for API production. Recognized as a National High-Tech Enterprise, Zhejiang Provincial Sci-Tech Enterprise, Zhejiang SRDI SME, and a key industrial enterprise in Jiande City, the company maintains a strong commitment to quality and innovation.